… As CML mainly affects elderly patients and treatment with TKI is so effective, many CML
patients die meanwhile from causes unrelated to CML and its treatment. Other patients die with …

… In this study, we retrospectively analyzed the clinical features and outcome of 89 French
CML patients harboring 94 mutations detected at the time of imatinib resistance. We determined …

… STI571 (IRIS) trial that investigated the use of the tyrosine kinase inhibitor (TKI) imatinib (versus
interferon) changed the treatment and outcome of chronic myeloid leukemia (CML). Long…

… -based CML registry in the Netherlands capturing data from newly diagnosed CML patients
in … Detailed information was collected on the patients’ characteristics and their treatment, both …

… It is not known if such patients will require … clinical outcomes in two patients with chronic
phase CML who discontinued imatinib therapy after obtaining a molecular remission; one patient …

… The influence of comorbidities on outcome in CML patients has not been studied; … of different
TKIs for CML patients. We sought to identify the comorbidities in CML patients at diagnosis …

… -CML patients … -CML patients in Europe after 3 years of follow-up from the SIMPLICITY
observational study. Treatment monitoring, clinical response outcomes, and predictors of clinical …

… The advent of tyrosine kinase inhibitors (TKIs) has dramatically improved the outcome of
patients with chronic myeloid leukemia (CML). Currently, four TKIs are available for the frontline …

… has so far included more than 900 patients. Evaluating updated information from this
registry… , clinical characteristics at diagnosis, clinical outcome, and adherence to national CML …

… The literature on the HRQL of CML patients is limited, characterized by studies inclusive of
other leukemias and cancer indications in which transplantation was the selected treatment …